• Ping Rong, Qianfang Fu, Xilian Zhang, Xuan Liu, Jie Yang, Xin Wang, Shuai Wang, Hui Liu, Rong Ma, and Lianghui Nie.
• Department of Pediatrics, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Xiqing.
• Medicine (Baltimore). 2021 Mar 12; 100 (10): e25134e25134.

BackgroundEpilepsy is 1 of the common neurodevelopmental diseases. It can affect about 0.5% to 1.0% of the population regardless of their race and social class. Despite the development of a wide range of treatments, there remaining about one-third of patients still experience seizures. Chinese herbal compounds containing scorpion (CHCCS) have shown an outstanding curative effect on nerve protection and epilepsy. But there's no study to assess its clinical efficacy and safety.MethodsEach data of CHCCS in treating epilepsy from related English and Chinese databases will be searched. The primary outcome is the efficacy of the CHCCS on epilepsy. And the secondary outcomes include recurrence rate and side effects. The risk of bias will be assessed, and RevMan5.3 and Stata14.0 will be performed for meta-analysis. Finally, we will assess the level of the resulting evidence.ResultsThe results of the study will be combined with current evidence and published in a peer-reviewed journal.ConclusionsThis study will specifically investigate the effectiveness and safety of CHCCS in treating epilepsy.Inplasy Registration NumberINPLASY202120056.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

28 keywords...

hide…